Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +47.86%
#3 MetaDAO MetaDAO +29.20%
#4 Rain Rain +23.12%
#5 Bedrock Bedrock +19.74%
#6 Pons Pons +18.81%
#7 Prom Prom +17.17%
#8 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +16.51%
#9 Ontology Gas Ontology Gas +15.02%
#10 Humanity Humanity +14.89%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
Gracell Biotechnologies Inc. Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc.

GRCL
Rank in Stocks #20198
Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company... Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of cell-based therapies, primarily for cancer treatment, within the People's Republic of China. The company's leading investigational therapies include: GC012F: A FasTCAR-enhanced autologous CAR-T product designed to target both BCMA and CD19, currently undergoing Phase I clinical trials for multiple myeloma. GC019F: A FasTCAR-enabled CD19-directed autologous CAR-T therapy, which is progressing through Phase I trials for adult B-cell acute lymphoblastic leukemia (B-ALL) and is also in preclinical development for relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL). GC027: A TruUCAR-powered allogeneic CAR-T product targeting CD7, presently in Phase I clinical development for adult T-cell acute lymphoblastic leukemia. Additionally, Gracell's pipeline features: GC007g: A donor-derived allogeneic CAR-T cell therapy directed at CD19, currently in a Phase 1/2 registrational study for r/r B-ALL. GC502: An off-the-shelf, TruUCAR-enabled allogeneic CAR-T candidate engineered to target both CD19 and CD7, which is in Phase I trials for B-cell malignancies. Beyond these, Gracell maintains a broader portfolio of earlier-stage therapeutic candidates addressing diverse oncological conditions, including ovarian cancer, breast cancer, peripheral T cell lymphoma (a subtype of NHL), and T cell lymphoblastic leukemia. Established in 2017, the company's headquarters are situated in Suzhou, China.
Share Price
$10.25
Last synced: 2024-02-22
Market Cap
$137.83M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CN
Trade Gracell Biotechnologies Inc. (GRCL)

Category

Healthcare
Stock price history for Gracell Biotechnologies Inc. (GRCL)
Highest end of day price: $10.24 on 2024-02-01

Lowest end of day price: $22.88 on 2021-01-01
Stock price history of Gracell Biotechnologies Inc. from 2021 to 2026
Annual Stock Price Performance
Year Performance
2024 60.59%
2023 155.25%
2022 -61.61%
2021 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 50.56%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 525.80%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.47 -12.71%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $772.27 8.67%
CH